Novo Nordisk in Danish price war
The diabetes giant Novo Nordisk has lowered the price on its long-acting insulin, Levemir, on the Danish market in a bid to gain the same reimbursement status as a major competitor.
by Stefan Singh Kailay
First Sanofi lowered the price of Lantus and now Novo Nordisk is lowering the price on one of its best-selling diabetes products – the long-acting basal insulin, Levemir.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
